Beers Criteria

The criteria explicitly identify drug classes with an unfavorable risk-benefit ratio in geriatric populations. Key categories include:

• First-generation antihistamines (e.g., diphenhydramine) due to anticholinergic effects causing confusion and urinary retention
• Tricyclic antidepressants (e.g., amitriptyline) linked to orthostatic hypotension and cardiac conduction abnormalities
• Long-acting benzodiazepines (e.g., diazepam) associated with prolonged sedation and increased fall risk
• Non-COX-selective NSAIDs (e.g., indomethacin) in patients with Stage 4 or higher chronic kidney disease

The Beers Criteria cross-references medications against specific geriatric syndromes to flag drug-disease interactions where a drug may exacerbate an existing condition:

• Antipsychotics in patients with dementia due to increased cerebrovascular accident and mortality risk
• Peripheral alpha-1 blockers (e.g., doxazosin) in women with stress incontinence due to exacerbation of symptoms
• Opioids in patients with a history of falls or fractures, increasing the likelihood of recurrent injury
• Acetylcholinesterase inhibitors in patients with syncope due to bradycardia risk

The criteria catalog high-severity drug-drug interactions prevalent in polypharmacy regimens. Automated systems use these rules to flag combinations such as:

• Three or more CNS-active drugs concurrently, dramatically increasing fall and cognitive impairment risk
• Warfarin combined with NSAIDs, elevating the risk of life-threatening gastrointestinal hemorrhage
• Lithium with ACE inhibitors, which can precipitate lithium toxicity through reduced renal clearance
• Opioids with gabapentinoids, potentiating respiratory depression beyond either agent alone

A dedicated subset of the criteria lists medications requiring dose reduction or complete avoidance based on creatinine clearance thresholds:

• Dabigatran at CrCl < 30 mL/min due to accumulation and bleeding risk
• Spironolactone at CrCl < 30 mL/min linked to dangerous hyperkalemia
• Enoxaparin at CrCl < 30 mL/min requiring anti-Xa monitoring or alternative anticoagulation
• Nitrofurantoin at CrCl < 30 mL/min due to inadequate urine concentration for efficacy and peripheral neuropathy risk

The Beers Criteria explicitly ranks medications by their anticholinergic potency to help clinicians minimize cumulative burden. High-potency agents to avoid include:

• Scopolamine and atropine for their potent central nervous system effects
• Oxybutynin immediate-release for overactive bladder, with preferential use of non-anticholinergic alternatives like mirabegron
• Paroxetine among SSRIs due to its uniquely strong muscarinic receptor affinity
• The criteria emphasize that combining multiple agents with even moderate anticholinergic activity can produce a cumulative toxic effect manifesting as delirium, constipation, and functional decline

The American Geriatrics Society maintains the criteria through a rigorous, transparent update cycle approximately every three years:

• Systematic literature review conducted by an expert panel using the GRADE methodology
• Each recommendation carries an explicit Quality of Evidence rating (High, Moderate, Low) and a Strength of Recommendation designation (Strong, Conditional)
• The 2023 update introduced new PIMs including glimepiride and sliding-scale insulin due to hypoglycemia risk
• This structured evidence framework allows automated clinical decision support systems to weight alerts by clinical significance, reducing alert fatigue from low-evidence flags

A quantitative metric that stratifies a patient's risk of adverse geriatric outcomes by calculating the total number of concurrent medications, often weighted by anticholinergic or sedative burden. This score operationalizes Beers Criteria compliance by providing a single, trackable number that flags high-risk regimens before clinical events occur.

• Integrates Drug Burden Index (DBI) calculations
• Flags cumulative CNS depressant effects
• Triggers pharmacist review at predefined thresholds

Validated measurement tools such as the Anticholinergic Cognitive Burden (ACB) Scale and the Anticholinergic Risk Scale (ARS) that quantify the cumulative cognitive impact of medications with muscarinic receptor antagonism. These scales complement the Beers Criteria by providing a graded severity framework rather than a binary avoid/use classification.

• ACB scores range from 0 (none) to 3 (severe)
• Cumulative scores ≥3 correlate with measurable cognitive decline
• Used to deprescribe high-burden Beers-listed drugs

The clinical rules engine that evaluates a patient's estimated glomerular filtration rate (eGFR) against drug monographs to flag medications requiring reduced dosage or discontinuation. The Beers Criteria explicitly identifies drugs that are renally inappropriate in older adults, making this logic a mandatory downstream check after initial Beers screening.

• Uses Cockcroft-Gault or CKD-EPI equations
• Flags drugs like dabigatran, enoxaparin, and gabapentin
• Prevents accumulation toxicity in age-related renal decline

The American Geriatrics Society (AGS) maintains the Beers Criteria through a rigorous, periodic expert panel review process. Each update cycle evaluates new evidence, adds emerging high-risk medications, and refines existing recommendations based on systematic literature reviews and Delphi consensus methodology.

• Updated approximately every 3 years (2012, 2015, 2019, 2023)
• 2023 update added SGLT2 inhibitors cautions
• Explicitly categorizes drugs by quality of evidence and strength of recommendation